

ASCEND: A phase 1/2, dose-escalation, optimization, and dose-expansion study to evaluate the safety and antitumor activity of CR-001 in adults with locally advanced or metastatic solid tumors

Ana Oaknin¹, Amita Patnaik², Rebecca Kristeleit³, Seung Tae Kim⁴, Emily Putiri⁵, Lindsey Granlund⁵, Paul Herszdorfer⁵, Bradley Sumrow⁵, Meredith Pelster⁶

¹Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain; ²The START Center for Cancer Research, San Antonio, Texas, USA; ³Guy's and St. Thomas' NHS Foundation Trust, London, UK;

⁴Samsung Medical Center, Seoul, Korea; ⁵Crescent Biopharma, Inc., Waltham, MA, USA; ⁶Sarah Cannon Research Institute, Nashville, TN, USA

#1141eTIP

Background

- CR-001 is a tetravalent bispecific antibody targeting programmed cell death-1 (PD-1) and vascular endothelial growth factor (VEGF) (**Figure 1**), designed to enhance antitumor activity through combined immune modulation and antiangiogenic effects.


- The proposed mechanism of action of CR-001 involves dual binding and blockade of both PD-1/programmed death-ligand 1 (PD-L1) and VEGF/vascular endothelial growth factor receptor 2 (VEGFR2) signaling.

- The blockade of VEGF signaling is aimed at inhibiting tumor angiogenesis and reversing immunosuppressive effects in the tumor microenvironment, while PD-1 binding is aimed at preventing T-cell suppression, thereby promoting the immune recognition and elimination of tumor cells.

- The established benefit/risk profiles and regulatory precedents for PD-1-, VEGF-, and dual-pathway-directed antibodies support evaluation of CR-001 in solid tumors.

- In this poster, we describe the design of ASCEND, a global, first-in-human, open-label, phase 1/2 study evaluating CR-001 as monotherapy and in combination with chemotherapy among patients with locally advanced or metastatic tumors.

Figure 1. CR-001



Study design


- ASCEND (NCT07335497) is a global, first-in-human, open-label, phase 1/2 study evaluating CR-001 monotherapy and chemotherapy combinations in adult participants with locally advanced or metastatic solid tumors.

- The purpose of this study is to determine the safety and tolerability of CR-001 and identify the maximum tolerated dose, and/or RP2D. Objectives and endpoints of the ASCEND study are detailed in the table opposite.

- The study consists of four parts: dose escalation, backfill, dose expansion, and dose optimization (**Figure 2**).

- Key inclusion/exclusion criteria are detailed on the right of the poster.

Figure 2. ASCEND study design



Study objectives

Primary (all cohorts)

- Characterize the safety and tolerability of CR-001 as a single agent and in combination with chemotherapy in participants with locally advanced or metastatic solid tumors

Primary (part 3 – dose expansion)

- Characterize the preliminary antitumor activity of CR-001 in combination with chemotherapy by ORR

Secondary (all cohorts)

- Identify the RP2D(s) of CR-001 based on the totality of safety, tolerability, PK, PD, and clinical activity data
- Characterize the PK profile of CR-001
- Characterize the immunogenicity of CR-001

Secondary (dose escalation, backfill and dose optimization)

- Characterize the preliminary antitumor activity of CR-001

Secondary (dose expansion)

- Characterize the preliminary antitumor activity of CR-001 in combination with chemotherapy

Eligibility criteria


Key inclusion criteria

- For dose escalation or backfill only: progressing from, intolerant to, or ineligible for (due to unavailability or contraindication) local standard of care therapies and have and have locally advanced/metastatic disease of one of the tumor types listed in Fig 2.
- Earlier-line participants, including those untreated in the advanced or metastatic setting, may also be eligible to participate in backfill cohorts.
- Life expectancy ≥3 months.
- ECOG PS score of 0–1.
- Adequate organ function and hematologic reserve based on laboratory parameters.
- Measurable disease defined by RECIST v1.1.
- For backfill, dose expansion, and dose optimization: willingness to provide recent archival tumor tissue sample or willingness to undergo biopsy.

Key exclusion criteria

- Malignancies other than disease under study within the past 3 years.
- History of prior Grade ≥3 immune-related adverse event on immunotherapy.
- History of drug-related pulmonary conditions, including Grade ≥2 pneumonitis, pulmonary fibrosis.

Active study sites and current status



- Up to 540 patients are planned to be enrolled across the dose-escalation, tumor-specific backfill, and dose-optimization cohorts.
- This trial is currently enrolling in the US, Ireland, Italy, Romania, South Korea, Spain, the UK and France.
- Further global expansion is planned.

CR-001
ClinicalTrials.gov
NCT07335497



Abbreviations

CRC, colorectal cancer; **DL**, dose level; **ECOG PS**, Eastern Cooperative Oncology Group performance status; **GEJ**, gastroesophageal junction; **MSS**, microsatellite stable; **NSCLC**, non-small cell lung cancer; **ORR**, overall response rate; **PD**, pharmacodynamics; **PD-1**, programmed cell death-1; **PD-L1**, programmed death ligand-1; **PK**, pharmacokinetics; **pMMR**, proficient mismatch repair; **RECIST**, Response Evaluation Criteria in Solid Tumors; **RP2D**, recommended phase 2 dose; **VEGF**, vascular endothelial growth factor; **VEGFR2**, vascular endothelial growth factor receptor 2.

Acknowledgements and disclosures

- The authors would like to thank all patients, their families, and investigators involved in the study.
- Protocol CR-001-101 is sponsored by Crescent Biopharma, Inc.
- Crescent Biopharma, Inc. funded the editorial/creative assistance for this poster, which was provided by Miller Medical Communications Ltd.
- The presenting author, Dr Ana Oaknin, has the following COIs to disclose:
 - Advisory board (personal)**: Abbvie, Agenus, AstraZeneca, Biontech, BMS, Clovis Oncology, Concept Therapeutics, Daiichi Sankyo, Debiopharm International, Deciphera Pharmaceuticals, Eisai, Exelixis, F. Hoffmann-La Roche, Genmab, GSK, Immunogen, Ipsen, Itheos, Lilly, Medison Pharma Trading AG, Mersana Therapeutics, MSD, Myriad Genetics, Novocure, OncoXerna Therapeutics, Inc, Ottimo, Pharmaand, PharmaMar, Regeneron, Sattucklabs, Seagen/Pfizer, Stemline Therapeutics, Sutro Biopharma, TORL Therapeutics, Zentalis, Zymeworks.
 - Travel and accommodation (personal)**: AstraZeneca, PharmaMar, Roche.